# Innovation, Adaptation, and Human Dignity in Assistive Robotics in Amyotrophic Lateral Sclerosis: A Rehabilitation Medicine Perspective

**Authors:** Rafaelle B Azarraga, Mark C Jackson, Marcel P Fraix, Devendra K Agrawal

PMC · DOI: 10.26502/jbb.2642-91280207 · Journal of biotechnology and biomedicine · 2026-03-10

## TL;DR

This paper reviews how assistive robotics can improve the quality of life for ALS patients by helping them maintain independence and perform daily tasks.

## Contribution

The paper provides a rehabilitation medicine perspective on the emerging field of assistive robotics for ALS, emphasizing humanistic and ethical considerations.

## Key findings

- Assistive robotics can significantly impact the quality of life for ALS patients by preserving physical capabilities and autonomy.
- Barriers such as cost, accessibility, and ethical issues need to be addressed for broader adoption of these technologies.
- There is a lack of robust, case-controlled studies specifically addressing the use of robotics in ALS rehabilitation.

## Abstract

Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive motor neuron disease that heavily impacts a person’s ability to perform activities of daily living, affecting mobility, function, and communication drastically. These complications present a daunting obstacle for familial support systems and physicians to manage. Although survival prognosis in ALS patients has moderately improved with the advent of ALS specialty clinics, this illness persists as a grim diagnosis with no current cure or hope for recovery, simply an inescapable decline. However, assistive robotics provides a promising opportunity in empowering patients to retain control of their lives. This comprehensive review explores the current developments in assistive robotics for ALS patients across various aspects of daily living. Our review accentuates how robotics can make a significant impact on quality of life, preserving physical capabilities and patient agency. Potential barriers have also been identified, such as cost, accessibility and ethical considerations. However, there is limited information with case-controlled studies and robust research addressing ALS from this scope. Within the lens of rehabilitation, these technologies present the opportunity to preserve autonomy, the ability to still care for oneself, to perform the “everyday” tasks, the things that make life still meaningful. This critical review highlights the humanistic potential that the future of this emerging field holds; to innovate and bridge the technical with the personal; and to approach decline with empathy, adaptability and respect.

## Linked entities

- **Diseases:** Amyotrophic Lateral Sclerosis (MONDO:0004976)

## Full-text entities

- **Genes:** C9orf72 (C9orf72-SMCR8 complex subunit) [NCBI Gene 203228] {aka ALSFTD, DENND9, DENNL72, FTDALS, FTDALS1}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, TARDBP (TAR DNA binding protein) [NCBI Gene 23435] {aka ALS10, TDP-43}, FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}
- **Diseases:** spasticity (MESH:D009128), neurodegenerative disease (MESH:D019636), eye-gaze tiredness (MESH:D015835), inflammation (MESH:D007249), ALS (MESH:D000690), Motor decline (MESH:D060825), weakness (MESH:D018908), toxicity (MESH:D064420), neuronal (MESH:D009410), motor neuron disease (MESH:D016472), Speech impairments (MESH:D013064), paralysis (MESH:D010243), fatigue (MESH:D005221), dysarthria (MESH:D004401), glutamate (MESH:C537425), stroke (MESH:D020521), loss of voluntary motor control (MESH:D009155), muscular dystrophy (MESH:D009136), spinal cord injury (MESH:D013119), neuromuscular diseases (MESH:D009468), quadriplegia (MESH:D011782), motor dysfunction (MESH:D000068079)
- **Chemicals:** edaravone (MESH:D000077553), riluzole (MESH:D019782)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12970945/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12970945/full.md

## References

96 references — full list in the complete paper: https://tomesphere.com/paper/PMC12970945/full.md

---
Source: https://tomesphere.com/paper/PMC12970945